Long Read Sequencing Market – Global Forecast To 2029
The long-read sequencing market is expected to reach USD 3,129 million in 2029 from USD 758 million in 2024, at a CAGR of 32.8% during the forecast period.
ロングリードシーケンス市場は、予測期間中に32.8%のCAGRで、2024年の7億5,800万米ドルから2029年には31億2,900万米ドルに達すると予想されます。
Growth in the long-read sequencing market is mainly driven by factors like increasing collaborations between academic institutions and industry players, decreased cost of sequencing, and continuous technological advancements in long-read sequencing. Moreover, the application of LRS like de novo genome assembly, structural variant detection, transcriptomics, and epigenetics is supporting the market growth. However, the initial cost concern to set up the equipment is impacting the growth of the long-read sequencing market.
The report provides insights on the following pointers:
Analysis of key drivers (Technological advancements in genome sequencing, Increased prevalence of complex and rare genetic disorders, and growing demand for high-quality throughput screening), restraints (High investments to develop long read sequencing technologies, Technical Limitations of existing technology), opportunities (Rising demand for long-read sequencing in clinical genomics, and expanding applications of long-read sequencing), and challenges (challenges associated with data preservation, analysis, and validation) influencing the growth of the market.
- Product Development/Innovation: Detailed insights on newly launched services of the long-read sequencing market
- Market Development: Comprehensive information about lucrative markets – the report analyses the market across varied regions.
- Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the long-read sequencing market
- Competitive Assessment: Oxford Nanopore Technologies plc. (UK), PacBio (US), Illumina, Inc. (US), Agilent Technologies, Inc. (US), Thermo Fisher Scientific Inc. (US), 10X Genomics, Inc. (US), QIAGEN (Germany), BGI Group (China), Takara Bio Inc. (Japan), Azenta US, Inc. (US), Revvity, Inc. (US), Danaher Corporation (US), Novogene Co., Ltd. (China), New England Biolabs (US), BaseClear BV (Netherlands), Element Biosciences (US), Grandomics (China), CD Genomics (US), Sage Sciences, Inc. (US), and EdenRoc Sciences (US) among others in the market.